SCHEDULE 13G/A: Lynx1 Capital Management and Weston Nichols Disclose 15% Stake in Passage BIO, Inc.

Lynx1 Capital Management LP and Weston Nichols have reported a 15.0% beneficial ownership stake in Passage BIO, Inc., holding 9,256,953 shares of common stock as of December 31, 2024.

Summary

• Lynx1 Capital Management LP and Weston Nichols (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Passage BIO, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 9,256,953 shares of Passage BIO, Inc. Common Stock.
• This ownership represents 15.0% of the total outstanding Common Stock of Passage BIO, Inc.
• The percentage is calculated based on 61,767,286 shares of Common Stock outstanding as of November 8, 2024, as reported in Passage BIO's Form 10-Q for the quarter ended September 30, 2024.
• Both Lynx1 Capital Management LP and Weston Nichols hold shared voting and shared dispositive power over all 9,256,953 shares.
• The shares are directly held by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP acts as the investment manager.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Passage BIO, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive investment by an institutional entity, which can be viewed positively as a vote of confidence in Passage BIO, Inc. However, it contains no operational or financial performance data from the company itself, so the sentiment is primarily neutral to slightly positive based on the investment.

Positives

• A significant institutional investor, Lynx1 Capital Management LP, and its principal, Weston Nichols, have taken a substantial 15.0% stake in Passage BIO, Inc., which can be interpreted as a vote of confidence in the company.
• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing control, suggesting a passive investment intent rather than an activist one.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Passage BIO, Inc. regarding its future outlook.

Management Comments

• The filing includes a certification by the Reporting Persons that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant investment by a capital management firm in Passage BIO, Inc., a company operating in the biotechnology sector. Such substantial passive investments by institutional entities are common in the biotech industry, where long-term capital is often required for research and development, and can signal investor confidence in a company's pipeline or strategic direction.

Comparison to Industry Standards

• This document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain financial or operational results that can be directly compared to industry benchmarks or specific comparable companies. It solely reports the ownership stake of a specific investor.

Stakeholder Impact

• Shareholders: The disclosure of a significant 15.0% stake by an institutional investor may be perceived positively, potentially signaling confidence in the company's long-term prospects and stability of its shareholder base.
• Management: The certification that the investment is not for control purposes suggests that current management is unlikely to face immediate activist pressure from this specific investor, allowing them to focus on strategic execution.

Key Dates

Keywords

Passage BIO Inc., Lynx1 Capital Management LP, Weston Nichols, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Biotechnology, Pharmaceuticals